Relevancy of Nizatidine Release from Floating Tablets with Viscosity of Various Cellulose Ethers

Abstract

Nizatidine is a gastroprotective drug with a short biological half-life and narrow absorption window. This study aimed at developing floating tablets of nizatidine using various HPMC viscosity grades, namely K4M, E4M, K15 and K200M. Directly compressed tablets revealed an excellent uniformity in hardness, thickness and weight and nizatidine was evenly distributed within the matrix floating tablets. Buoyancy study revealed floating lag time as low as 18–38 s, and tablets remain buoyant for upto 24 h. However, the later depended upon viscosity grade of HPMC and that the higher the viscosity, the less was the total floating time. In vitro dissolution indicated viscosity dependent nizatidine release from the floating tablets. HPMC K4M and E4M based floating tablets released almost 100% drug in 12 h, whilst higher viscosity polymers such as K15 and K200M only released 81.88% and 75.81% drug, respectively. The drug release followed non-Fickian diffusion from tablets formulated with K4M, K15 and K200M, whilst super case II transport was observed with E4M based tablets. More interestingly, K4M and E4M polymers have similar viscosity yet exhibited different drug release mechanism. This was attributed to the difference in degree of substitution of methoxyl- and hydroxypropoxyl- groups on polymer backbone.

Glutaraldehyde-crosslinked chitosan-polyethylene oxide nanofibers as a potential gastroretentive delivery system of nizatidine for augmented gastroprotective activity

“…Hence, the improvement of NIZ delivery and efficacy may reduce the therapy duration and the incidence of this interaction. Accordingly, several studies have been carried out to develop NIZ GRDDSs such as floating pulsatile tablets (Rathnanand & Pannala, 2011 ), floating osmotic tablet (Sarkar et al, 2014 ), microballoons (Jain et al, 2015 ), effervescent gastroretentive tablets (Orugonda et al, 2017 ), floating tablets (Shahzad et al, 2019 ), and effervescent floating tablets (Reddy & Tahseen, 2020 ). These studies did not involve extensive in vivo evaluation.…”